An observational study in Dysautonomia and Dysautonomia Like Disorder, sponsored by Life University. Completed at 1 site in Pakistan. Open to participants aged 5 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Life University · Observational
To investigate the feasibility of implementing an online assessment battery in tandem with normal \& customary complementary \& integrative healthcare (CIH) provided to children with dysautonomia. The secondary aim is to assess the potential impacts of CIH on clinical outcomes.
The main aim of this pilot observational study is to investigate the feasibility of implementing an online assessment battery in tandem with normal \& customary, fee-for-service, remotely delivered complementary \& integrative healthcare (CIH, i.e., Neuro-Emotional Release: Veins \& Endocrine System [NERVE] therapy) provided to children with significant parent-reported symptoms of dysautonomia. The primary outcomes are 1) eligibility, 2) compliance, 3) adherence, and 4) retention. A secondary/exploratory aim is to assess the potential clinical impacts of CIH via a validated parent-reported outcome measure (i.e., Pediatric Autonomic Symptom Scales, PASS; Short Sensory Profile, SSP). Data from this study will inform the feasibility of a definitive study powered to assess the effectiveness of NERVE therapy on clinical outcomes in a pediatric population with symptoms of dysautonomia.
108 studies on the registry are indexed under Autonomic Nervous System Diseases; 29 are open to participants now.
This study's enrollment of 25 is below the median of 69 across 34 observational studies indexed under Autonomic Nervous System Diseases.
Browse Autonomic Nervous System Diseases studies →Life University is the lead sponsor of 29 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Children aged 5-14 years whose parents/caregivers identify the presence of symptoms associated with dysautonomia. A formal clinical diagnosis is not required for inclusion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children aged 5-14 years whose parents/caregivers identify the presence of symptoms associated with dysautonomia. A formal clinical diagnosis is not required for inclusion
Proportion of enrollees who are eligible to participate
The number of enrollees (i.e., participants who consent) who score ≥20 on the baseline Pediatric Autonomic Symptom Scales (PASS), divided by the total number of enrollees. This assesses 'Eligibility'.
Time frame: From enrollment to baseline PASS submission (up to 48-hours)
Proportion of surveys completed
The number of online surveys submitted within the prespecified time window (72 hours), divided by the total number of online surveys distributed (excludes surveys scheduled after withdrawal). This assesses 'Compliance'
Time frame: From enrollment to the end of participation (up to 12 weeks)
Proportion of participants adhering to the care plan
The number of participants attending ≥90% of scheduled remote care sessions , divided by the total number of participants (excludes care sessions scheduled after withdrawal). This assesses 'Adherence'
Time frame: From enrollment to the end of participation (up to 12 weeks)
Proportion of participants retained in the study
The number of eligible participants attending the final remote care session, divided by the total number of eligible participants. This assesses 'Retention'.
Time frame: From enrollment to the end of the 12 week study period
Change in Pediatric Autonomic Symptom Scales (PASS) scores
Change in PASS scores from baseline. The PASS is validated 80-item parent-report questionnaire designed to assess autonomic function in children across four main subscales: 1) mood, behavior, and emotion; 2) secretomotor/sensory integration; 3) urinary/gastrointestinal systems; 4) circulation, thermoregulation, sleep, and breathing. PASS total scores can range from 0 (no autonomic symptoms) to 80 (severe dysautonomia).
Time frame: Baseline; ~4 weeks; ~8 weeks; ~12 weeks
Change in Short Sensory Profile (SSP) scores
Change in SSP scores from baseline. The SSP is a validated 38-item parent-report designed to assess a child's responsiveness to sensory stimuli including tactile sensitivity, taste/smell sensitivity, and visual/auditory sensitivity. SSP total scores can range from 38 (extreme sensitivity) to 190 (no sensitivity).
Time frame: Baseline; ~4 weeks; ~8 weeks; ~12 weeks
Plan to share: Yes — Deidentified IPD necessary to reproduce results
Supporting information: Analytic code
Time frame: (start date): within 1 year of study completion. (end date): indefinitely
Access criteria: IPD, metadata \& analytic code necessary to reproduce results will be made publicly accessible via a data repository
Data sharing details ↗ · figshare.com
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Autonomic Nervous System Diseases →
Life University